CBD-CBDA Cannabinoid Composition for Stable Anti-Inflammatory Use
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for inflammatory conditions and autoimmune diseases, particularly TNF inhibitors, often fail to provide effective relief and can be harmful, necessitating the development of alternative anti-inflammatory and immunosuppressant agents.
Innovation Solution
A pharmaceutical composition comprising a 1:1 equimolar mixture of CBD and CBDA, potentially combined with other cannabinoids, is used to treat or prevent inflammation and autoimmunity, including autoimmune diseases such as rheumatoid arthritis and Crohn's disease, by reducing cytokine levels and inducing autophagy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional extraction methods (supercritical fluid extraction, ultrasound-assisted extraction, accelerated solvent extraction) are used, then extraction efficiency is improved, but the compositions remain unstable and require storage at -20°C or lower
Solution Approach 1:
The patent changes the physical state parameter of the cannabinoid composition by freeze-drying the extract to create a solid amorphous matrix. This parameter change from liquid to solid state, combined with the amorphous structure, stabilizes the composition and eliminates the need for refrigerated storage while maintaining extraction efficiency
2Productivity
If conventional extraction methods are used, then extraction efficiency is improved, but batch-to-batch variability increases
Solution Approach 1:
The patent applies preliminary action by performing freeze-drying on the entire extract batch before any further processing or storage. This preliminary stabilization step ensures that all subsequent handling occurs with a stable solid material, preventing variability that would arise from liquid-state inconsistencies during storage or processing
Solution Approach 2:
The patent creates a composite material structure where cannabinoids are embedded in an amorphous solid matrix formed during freeze-drying. This composite structure locks the cannabinoids in a stable configuration, ensuring consistent properties across batches regardless of minor variations in extraction conditions
3Productivity
If conventional extraction methods are used, then extraction efficiency is improved, but additional purification steps are required
Solution Approach 1:
The patent extracts and removes water and volatile components from the extract through freeze-drying, leaving behind a concentrated solid composition. This taking out of water and volatiles during the freeze-drying process inherently purifies the cannabinoid composition, eliminating the need for additional purification steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CBD:CBDA mixture demonstrates significant anti-inflammatory and immunosuppressant activity, effectively reducing cytokine levels and inducing autophagy, outperforming individual components and traditional treatments.
Implementation Method 1
Freeze-dried cannabis flower extracts and infusions have been observed to maintain stability at room temperature and humidity for at least 6 months
Data Source
Figure 1A
Figure 1B
Figure 2A~2D
AI summary
This disclosure describes compositions including cannabinoids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer therapeutic. In some aspects, the cannabinoid is chosen from i) CBC, CBCA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBL, CBLA, CBN, CBNA, THCV, THCVA, and any combination thereof, and ii) an approximately 1:1 equimolar mixture of CBD:CBDA.